Savastano, C. and Lombardi, F. 2018. Response to Lapatinib-Capecitabine combination in a young patient with recurrent HER2-positive breast cancer refractory to two lines of therapy with anti-HER2 drugs: Risposta alla combinazione Lapatinib-Capecitabina in giovane paziente con recidiva di carcinoma della mammella HER2-positivo refrattario a due linee di terapia con farmaci anti-HER2. AboutOpen. 4, 1 (Oct. 2018), 162–165. DOI:https://doi.org/10.19156/abtpn.2018.0067.